Lenox Wealth Management Inc. Has $4.22 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Lenox Wealth Management Inc. cut its position in Novo Nordisk A/S (NYSE:NVO) by 3.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 81,642 shares of the company’s stock after selling 2,622 shares during the period. Novo Nordisk A/S accounts for approximately 1.2% of Lenox Wealth Management Inc.’s investment portfolio, making the stock its 19th biggest holding. Lenox Wealth Management Inc.’s holdings in Novo Nordisk A/S were worth $4,220,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of NVO. Carroll Financial Associates Inc. lifted its position in Novo Nordisk A/S by 3.2% in the 2nd quarter. Carroll Financial Associates Inc. now owns 11,805 shares of the company’s stock valued at $602,000 after acquiring an additional 369 shares in the last quarter. Capital Insight Partners LLC lifted its position in Novo Nordisk A/S by 1.7% in the 2nd quarter. Capital Insight Partners LLC now owns 17,049 shares of the company’s stock valued at $870,000 after acquiring an additional 285 shares in the last quarter. Crossmark Global Holdings Inc. lifted its position in Novo Nordisk A/S by 1.9% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 81,009 shares of the company’s stock valued at $4,135,000 after acquiring an additional 1,509 shares in the last quarter. Arlington Partners LLC lifted its position in Novo Nordisk A/S by 870.8% in the 2nd quarter. Arlington Partners LLC now owns 48,150 shares of the company’s stock valued at $2,458,000 after acquiring an additional 43,190 shares in the last quarter. Finally, Valeo Financial Advisors LLC lifted its position in Novo Nordisk A/S by 510.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 629 shares of the company’s stock valued at $32,000 after acquiring an additional 526 shares in the last quarter. Institutional investors own 7.36% of the company’s stock.

Shares of Novo Nordisk A/S stock traded up $1.50 during mid-day trading on Friday, hitting $57.87. 1,768,123 shares of the stock were exchanged, compared to its average volume of 1,410,802. Novo Nordisk A/S has a 12 month low of $43.12 and a 12 month high of $57.93. The company has a 50-day simple moving average of $53.15 and a 200 day simple moving average of $50.60. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $135.11 billion, a P/E ratio of 22.96, a P/E/G ratio of 2.28 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. The company had revenue of $4.51 billion for the quarter, compared to analysts’ expectations of $4.55 billion. Novo Nordisk A/S had a net margin of 32.44% and a return on equity of 75.48%. Analysts predict that Novo Nordisk A/S will post 2.45 EPS for the current year.

NVO has been the topic of several recent research reports. Bank of America raised their price target on shares of Novo Nordisk A/S from $355.00 to $400.00 and gave the company a “neutral” rating in a research report on Friday, September 13th. Pareto Securities raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Monday, August 5th. Citigroup raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 17th. Jefferies Financial Group cut shares of Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a research report on Friday, August 30th. Finally, ValuEngine raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $159.65.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Article: Stochastic Momentum Index (SMI)

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply